Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Banco de datos
Tipo del documento
Asunto de la revista
País de afiliación
Intervalo de año de publicación
1.
Opt Lett ; 46(17): 4240-4243, 2021 Sep 01.
Artículo en Inglés | MEDLINE | ID: mdl-34469984

RESUMEN

A scheme of quarter-overlapped microlens arrays (QOMLA) is proposed to improve the display performance of integral imaging (II). The theory and the design of QOMLA is presented by the combination of geometric optics and wave optics and is verified by the optical experiments. The angular sampling density of the II system can be doubled in each dimension to further increase the spatial resolution. Multiple central depth planes can be constructed by adjusting the spacing of the multilayers, so as to expand the depth of field (DoF). Furthermore, QOMLA is easier to process when compared with the single-layer microlens array, and it reduces processing costs.

2.
Zhongguo Shi Yan Xue Ye Xue Za Zhi ; 31(1): 8-16, 2023 Feb.
Artículo en Zh | MEDLINE | ID: mdl-36765470

RESUMEN

OBJECTIVE: To explore the expression pattern and clinical significance of Integral membrane protein 2A(ITM2A) in drug resistant patients with chronic myeloid leukemia (CML). METHODS: The expression of ITM2A in CML was evaluated by qRT-PCR, Western blot and immunocytochemistry. In order to understand the possible biological effects of ITM2A, apoptosis, cell cycle and myeloid differentiation antigen expression of CML cells were detected by flow cytometry after over-expression of ITM2A. The nuderlying molecular mechanism of its biological effect was explored. RESULTS: The expression of ITM2A in bone marrow of CML resistant patients was significantly lower than that of sensitive patients and healthy donors(P<0.05). The CML resistant strain cell K562R was successfully constructed in vitro. The expression of ITM2A in the resistant strain was significantly lower than that in the sensitive strain(P<0.05). Overexpression of ITM2A in K562R cells increased the sensitivity of K562R cells to imatinib and blocked the cell cycle in G2 phase(P<0.05), but did not affect myeloid differentiation. Mechanistically, up-regulation of ITM2A reduced phosphorylation in ERK signaling (P<0.05). CONCLUSION: The expression of ITM2A was low in patients with drug resistance of CML, and the low expression of ITM2A may be the key factor of imatinib resistance in CML.


Asunto(s)
Antineoplásicos , Leucemia Mielógena Crónica BCR-ABL Positiva , Humanos , Antineoplásicos/farmacología , Apoptosis , Resistencia a Antineoplásicos , Mesilato de Imatinib/farmacología , Mesilato de Imatinib/uso terapéutico , Células K562 , Leucemia Mielógena Crónica BCR-ABL Positiva/tratamiento farmacológico , Transducción de Señal
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA